/Investor DB

Lundbeckfonden Ventures — Full Portfolio

12 tracked investments · listed companies and verified rows first

Aura Biosciencesaurabiosciences.comin𝕏NASDAQ: AURA

Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.

BiotechHealthtechMedical DevicesCambridge, US

Elisabet de los Pinos, Ph.D.(Executive Officer, Director)Elisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)Lewis Geffen(Executive Officer)

Co-investorsAdvent Life SciencesChiesi VenturesColumbus Venture PartnersDroia VenturesForesite CapitalJazzya Investments+6 more

ImaraNASDAQ: ELVNMar 2019 · $63Macquired by Enliven Therapeutics · Feb 2023

Imara is a clinical-stage biopharmaceutical company developing small molecule therapeutics for unmet medical needs, currently advancing ELVN-001, a selective kinase inhibitor designed to treat chronic myeloid leukemia by targeting the BCR-ABL gene fusion.

BiotechCambridge, US

James G. McArthur(Executive Officer, Director)Christoph M. Adams(Executive Officer, Director)Richard Fair(President, Chief Executive Officer, Director)

BoardSara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)

Co-investorsBay City CapitalNew Enterprise Associates (NEA)Pfizer Venture InvestmentsRA CapitalAlexandriaArix Bioscience+3 more

Akamis Bioakamisbio.comin𝕏

Akamis Bio develops oncolytic immunotherapies for colorectal cancer treatment, aiming to offer alternatives to surgery that preserve patient function and quality of life.

BiotechDigital HealthHealthtechMedical Devices

Co-investorsARCH Venture PartnersSR One Capital ManagementIP GroupWestlake Village BioPartners

Amplyxamplyx.comMay 2020

Developing a new class of antifungal medicine to overcome limitations of current therapies.

Co-investorsBioBritGolden SeedsKeiretsu ForumPappas CapitalSofinnova Ventures3x5 Partners+4 more

Enteromeenterome.com

Enterome is a clinical-stage biotech developing off-the-shelf immunotherapies for a range of cancers, including glioblastoma, adrenal tumors, non-Hodgkin lymphoma, and colorectal cancer.

BiotechHealthtech

NMD Pharmanmdpharma.comin𝕏

NMD Pharma is a clinical-stage biotech company developing first-in-class small-molecule therapies that selectively target skeletal muscle to treat rare neuromuscular diseases and age-related conditions.

BiotechDeep TechHealthtechMedical DevicesAarhus, DK

Co-investorsJeito CapitalNovo HoldingsInkefRoche Venture Fund

Reneoreneo.deinDec 2020 · $95M

Reneo is an asset and investment management platform for decarbonizing residential real estate portfolios in Germany.

Climate TechEnterprise SoftwarePropTechGermany, DE

Lennart Börner(Founder & Co-CEO)inAlexander Graubner-Müller(Founder & Co-CEO)in

Co-investorsFoundamentalAbingworthAisling CapitalAmzak HealthEurazeoLakestar+4 more

Reneo Pharmaceuticalsreneopharma.comDec 2020 · $95M

Xoilac TV is a free online football (soccer) live-streaming platform serving fans in Vietnam, offering Full HD match broadcasts of European, Asian, Vietnamese, and international competitions.

ConsumerMedia & EntertainmentSports Tech

Co-investorsAisling CapitalNew Enterprise Associates (NEA)Pappas CapitalRiverVest Venture PartnersAbingworthAmzak Health+2 more

Tiburio TherapeuticsinDec 2018

BiotechCambridge, US

James G. McArthur(Executive Officer)Abraham N. Ceesay(Executive Officer)Christoph M. Adams(Executive Officer, Director)

BoardMette Kirstine Agger(Director)David Mott(Director)Sandip Agarwala(Director)

Co-investorsAlexandriaLongitude CapitalNew Enterprise Associates (NEA)

VarmXvarmx.comin

VarmX develops VMX-C001, a therapeutic medicine for treating severe bleeding in patients on Factor Xa anticoagulants and for emergency surgery settings.

BiotechHealthtechMedical Devices

Pieter Reitsma(Founder)inJohn Glasspool(Chief Executive Officer)in

Co-investorsBioGeneration VenturesInkefSound BioventuresYsios CapitalEICEQT Life Sciences+2 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Amplyx PharmaceuticalsKvantify

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.